GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kuvatris Therapeutics PXMD · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Kuvatris Therapeutics

Its shares trade under the ticker PXMD. It has been listed since 19 August 2022.

PaxMedica Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tarrytown, New York. The company went IPO on 2022-08-19. PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
19 Aug 2022
Employees
3

Leadership

Pay as last reported

  • Mr. Howard WeismanChief Executive Officer, since 2020$1.1m
  • Ms. Stephanie PrinceIR Contact Officer, since 2022

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • PaxMedica Inc focuses on anti-purinergic drug therapies for neurologic disorders including ASD and ME/CFS.
  • PAX-101 is an intravenous formulation of suramin targeting ASD and ME/CFS treatment.
  • The company's clinical-stage development aligns with rising global incidence of Long COVID-19 Syndrome.

Weaknesses

  • PaxMedica has only 3 full-time employees, limiting operational capacity.
  • The company's IPO on 19 August 2022 indicates limited financial resources.
  • Clinical-stage biopharmaceutical development requires significant capital investment.

Opportunities

  • Growing global incidence of ME/CFS and Long COVID-19 Syndrome presents market potential.
  • Suramin's potential application in treating viral-related disorders like Long COVID-19.
  • Advancement in clinical understanding of anti-purinergic therapies for neurologic symptoms.

Threats

  • Rising incidence of ME/CFS and Long COVID-19 Syndrome may increase competition.
  • Clinical-stage development faces regulatory hurdles in pharmaceutical industry.
  • Limited employee count may hinder rapid response to market changes.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.